Dalrada Financial Corp. (OTCQB: DFCO, “Dalrada”) is pleased to announce that Dalrada Heath has finalized the Company’s acquisition of U.S.-based Pacific Stem Cells, LLC. The inclusion of Newport Beach, California-based Pacific Stem Cells, LLC in Dalrada Health’s portfolio adds non-invasive drug-free alternative therapies to the Company’s healthcare products and service offerings, and the company anticipates the acquisition will increase Dalrada’s annualized revenue by $2.5MM during the next twelve months.
Pacific Stem Cells, LLC is led by a team of healthcare professionals who have built a solid reputation and loyal client base. The Company intends to set a new standard for the highest quality, laboratory tested stem cells, timely delivery, telemedicine portal, treatment protocols, management services, physician, and staff education.
Stem cells, the basic building blocks of life, are found in the body’s organs, tissues, blood, and immune system. Stem cells have the ability to regenerate into additional stem cells or differentiate into specialized cells, such as nerve, muscle, or blood cells.
As a drug-free non-invasive treatment for many internal health conditions, Pacific Stem Cells, LLC provides its clients regenerative therapy as a potential solution for the prevention, detection and treatment of cellular breakdown associated with aging and a variety of other conditions.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Stem Cell Therapy is sought to treat a wide variety of medical conditions, ranging from orthopedics, pain management, cardiology, pulmonology, rheumatology, chronic kidney disease (CKD), diabetes & diabetic neuropathy, neurology, autoimmune disorders and in surgical procedures. aesthetic, cosmetic and plastic surgical procedures, including wound healing and limb salvage, and also a recent study has shown benefits against severe COVID-19 using umbilical-cord derived mesenchymal stem cells. The global stem cells market size is expected to reach USD 17.9 billion by 2027, expanding at a CAGR of 8.2%.
Source: Biospace
